{
    "clinical_study": {
        "@rank": "80822", 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine how the immune systems of HIV-infected patients\n      react to 2 anti-HIV drug combinations."
        }, 
        "brief_title": "A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to two study arms for at least 48 weeks of treatment. Arm A receives\n      SQV SGC plus RTV plus two NRTIs of choice. Arm B receives EFV plus two NRTIs of choice.\n      NRTIs approved for study use are stavudine (d4T), didanosine (ddI), zidovudine (AZT),\n      lamivudine (3TC), Combivir, and zalcitabine (ddC). Abacavir is excluded. The following\n      immunology variables and HIV-1 viral characteristics will be evaluated during study visits:\n      CD4 and CD8 cell counts; naive and memory T-cells; T-cell activation markers (HLA-DR and\n      CD38); T-cells expressing T helper 1- (TH1-) and T helper 2- (TH2-) associated\n      intracytoplasmic cytokines; anti-CD3 T-cell activation responses; T-cell receptor V Beta\n      repertoire; cytotoxic T-lymphocyte (CTL) activity levels; lymph node histology (optional);\n      HIV-1 qualitative microcultures and viral phenotyping for non-syncytium-inducing (NSI) and\n      syncytium-inducing (SI) viral isolates. Laboratory determinations, adverse effects,\n      neurological exams (including mental status evaluations), and lipodystrophy parameters\n      (including fasting lipid profile and physical parameters) also are evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients may be eligible for this study if they:\n\n          -  Are HIV-positive.\n\n          -  Have a viral load of at least 5,000 copies/ml and a CD4 cell count greater than 75\n             cells/mm3.\n\n          -  Are at least 16 (need consent of parent or guardian if under 18).\n\n          -  Are able to complete the study.\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Have ever taken anti-HIV medications.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002448", 
            "org_study_id": "229S", 
            "secondary_id": "M61028"
        }, 
        "intervention": [
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Saquinavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Saquinavir", 
                "Ritonavir", 
                "Reverse Transcriptase Inhibitors", 
                "Efavirenz"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "Dosage Forms", 
            "Saquinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900951793"
                    }, 
                    "name": "UCLA Care Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Palo Alto Veterans Affairs Health Care System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "089030019"
                    }, 
                    "name": "Robert Wood Johnson Med School/UMDNJ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of Immune Reconstitution in HIV Infected Patients Treated With Fortovase (Saquinavir) SGC QD Plus Ritonavir QD Plus 2 NRTIs Vs Efavirenz QD Plus 2 NRTIs", 
        "overall_official": [
            {
                "last_name": "Mark Holodniy", 
                "role": "Principal Investigator"
            }, 
            {
                "last_name": "Joseph John", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Ronald Mitsuyasu", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002448"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 1999", 
        "study_design": "Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2001"
    }, 
    "geocoordinates": {
        "Palo Alto Veterans Affairs Health Care System": "37.442 -122.143", 
        "Robert Wood Johnson Med School/UMDNJ": "40.486 -74.452", 
        "UCLA Care Ctr": "34.052 -118.244"
    }
}